Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 174 entries
Sorted by: Best Match Show Resources per page
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.

Gynecologic oncology

Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C.
PMID: 34275654
Gynecol Oncol. 2021 Sep;162(3):686-693. doi: 10.1016/j.ygyno.2021.07.001. Epub 2021 Jul 16.

INTRODUCTION: Lynch syndrome is a multi-tumor syndrome characterized by mismatch repair deficiency (MMR-d), microsatellite instability (MSI), and increased tumor-infiltrating lymphocytes (TILs) making these tumors candidates for treatment with immune checkpoint inhibitors. However, response may depend on tumor-induced immune evasion...

Cite
Rasmussen M, Lim K, Rambech E, et al. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecol Oncol. 2021;162(3):686-693doi: 10.1016/j.ygyno.2021.07.001.
Rasmussen, M., Lim, K., Rambech, E., Andersen, M. H., Svane, I. M., Andersen, O., Jensen, L. H., Nilbert, M., & Therkildsen, C. (2021). Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecologic oncology, 162(3), 686-693. https://doi.org/10.1016/j.ygyno.2021.07.001
Rasmussen, Maria, et al. "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile." Gynecologic oncology vol. 162,3 (2021): 686-693. doi: https://doi.org/10.1016/j.ygyno.2021.07.001
Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecol Oncol. 2021 Sep;162(3):686-693. doi: 10.1016/j.ygyno.2021.07.001. Epub 2021 Jul 16. PMID: 34275654.
Copy Download .nbib Format: NLM
Renal Involvement in Children with Type 2 Diabetes Mellitus Onset: A Pilot Study.

Children (Basel, Switzerland)

Marzuillo P, Di Sessa A, Palma PL, Umano GR, Polito C, Iafusco D, Guarino S, Miraglia Del Giudice E.
PMID: 34438518
Children (Basel). 2021 Jul 23;8(8). doi: 10.3390/children8080627.

Type 2 Diabetes Mellitus (T2DM) is a main cause of chronic kidney disease (CKD) in adulthood. No studies have examined the occurrence of acute kidney injury (AKI)-that enhances the risk of later CKD-and renal tubular damage (RTD)-that can evolve...

Cite
Marzuillo P, Di Sessa A, Palma PL, et al. Renal Involvement in Children with Type 2 Diabetes Mellitus Onset: A Pilot Study. Children (Basel). 2021;8(8)doi: 10.3390/children8080627.
Marzuillo, P., Di Sessa, A., Palma, P. L., Umano, G. R., Polito, C., Iafusco, D., Guarino, S., & Miraglia Del Giudice, E. (2021). Renal Involvement in Children with Type 2 Diabetes Mellitus Onset: A Pilot Study. Children (Basel, Switzerland), 8(8), . https://doi.org/10.3390/children8080627
Marzuillo, Pierluigi, et al. "Renal Involvement in Children with Type 2 Diabetes Mellitus Onset: A Pilot Study." Children (Basel, Switzerland) vol. 8,8 (2021). doi: https://doi.org/10.3390/children8080627
Marzuillo P, Di Sessa A, Palma PL, Umano GR, Polito C, Iafusco D, Guarino S, Miraglia Del Giudice E. Renal Involvement in Children with Type 2 Diabetes Mellitus Onset: A Pilot Study. Children (Basel). 2021 Jul 23;8(8). doi: 10.3390/children8080627. PMID: 34438518; PMCID: PMC8392677.
Copy Download .nbib Format: NLM
Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study.

Kidney diseases (Basel, Switzerland)

Yue L, Pan B, Shi X, Du X.
PMID: 32523962
Kidney Dis (Basel). 2020 May;6(3):204-214. doi: 10.1159/000505850. Epub 2020 Feb 25.

BACKGROUND: Beta-2 microglobulin (B2M) and cystatin C are novel glomerular filtration markers that have a stronger association with adverse outcomes than creatinine. The B2M-based glomerular filtration rate (GFR) estimating equation was built in 2016. Several new creatinine and cystatin...

Cite
Yue L, Pan B, Shi X, et al. Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study. Kidney Dis (Basel). 2020;6(3):204-214doi: 10.1159/000505850.
Yue, L., Pan, B., Shi, X., & Du, X. (2020). Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study. Kidney diseases (Basel, Switzerland), 6(3), 204-214. https://doi.org/10.1159/000505850
Yue, Lili, et al. "Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study." Kidney diseases (Basel, Switzerland) vol. 6,3 (2020): 204-214. doi: https://doi.org/10.1159/000505850
Yue L, Pan B, Shi X, Du X. Comparison between the Beta-2 Microglobulin-Based Equation and the CKD-EPI Equation for Estimating GFR in CKD Patients in China: ES-CKD Study. Kidney Dis (Basel). 2020 May;6(3):204-214. doi: 10.1159/000505850. Epub 2020 Feb 25. PMID: 32523962; PMCID: PMC7265741.
Copy Download .nbib Format: NLM
First-week urine beta-2 microglobulin levels in term healthy neonates.

Pediatric nephrology (Berlin, Germany)

Tzvi-Behr S, Ivgi H, Frishberg Y, Ben Shalom E, Zhurba M.
PMID: 33387020
Pediatr Nephrol. 2021 Jun;36(6):1511-1514. doi: 10.1007/s00467-020-04839-2. Epub 2021 Jan 02.

BACKGROUND: Beta-2 microglobulin (β2mG) is a low-molecular-weight protein that is almost exclusively eliminated through the kidneys. It is freely filtered in the glomeruli and almost completely reabsorbed and degraded in the proximal tubules. Normal urinary β2mG levels are very...

Cite
Tzvi-Behr S, Ivgi H, Frishberg Y, et al. First-week urine beta-2 microglobulin levels in term healthy neonates. Pediatr Nephrol. 2021;36(6):1511-1514doi: 10.1007/s00467-020-04839-2.
Tzvi-Behr, S., Ivgi, H., Frishberg, Y., Ben Shalom, E., & Zhurba, M. (2021). First-week urine beta-2 microglobulin levels in term healthy neonates. Pediatric nephrology (Berlin, Germany), 36(6), 1511-1514. https://doi.org/10.1007/s00467-020-04839-2
Tzvi-Behr, Shimrit, et al. "First-week urine beta-2 microglobulin levels in term healthy neonates." Pediatric nephrology (Berlin, Germany) vol. 36,6 (2021): 1511-1514. doi: https://doi.org/10.1007/s00467-020-04839-2
Tzvi-Behr S, Ivgi H, Frishberg Y, Ben Shalom E, Zhurba M. First-week urine beta-2 microglobulin levels in term healthy neonates. Pediatr Nephrol. 2021 Jun;36(6):1511-1514. doi: 10.1007/s00467-020-04839-2. Epub 2021 Jan 02. PMID: 33387020.
Copy Download .nbib Format: NLM
Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation.

Medical science monitor : international medical journal of experimental and clinical research

Zhang B, Chen X, Mu X, Liu E, Liu T, Xu G, Bao Q, Li G.
PMID: 34803158
Med Sci Monit. 2021 Nov 22;27:e932813. doi: 10.12659/MSM.932813.

BACKGROUND Atrial fibrillation (AF) is the most common persistent arrhythmia that can cause complications (including stroke). Therefore, its diagnosis and treatment require increased attention. Although beta-2 microglobulin (b2-MG) is a novel marker of cardiovascular disease, its role in AF...

Cite
Zhang B, Chen X, Mu X, et al. Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation. Med Sci Monit. 2021;27:e932813doi: 10.12659/MSM.932813.
Zhang, B., Chen, X., Mu, X., Liu, E., Liu, T., Xu, G., Bao, Q., & Li, G. (2021). Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation. Medical science monitor : international medical journal of experimental and clinical research, 27e932813. https://doi.org/10.12659/MSM.932813
Zhang, Bangying, et al. "Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation." Medical science monitor : international medical journal of experimental and clinical research vol. 27 (2021): e932813. doi: https://doi.org/10.12659/MSM.932813
Zhang B, Chen X, Mu X, Liu E, Liu T, Xu G, Bao Q, Li G. Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation. Med Sci Monit. 2021 Nov 22;27:e932813. doi: 10.12659/MSM.932813. PMID: 34803158; PMCID: PMC8619805.
Copy Download .nbib Format: NLM
Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody.

PeerJ

Guo W, Zhang Y, Gao C, Huang J, Li J, Wang R, Chen B.
PMID: 32117644
PeerJ. 2020 Feb 21;8:e8650. doi: 10.7717/peerj.8650. eCollection 2020.

BACKGROUND: To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody.METHOD: Overall, 229 IMN patients were retrospectively collected in this study and classified into anti-PLA2R antibody-negative (PLA2R-, 59...

Cite
Guo W, Zhang Y, Gao C, et al. Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody. PeerJ. 2020;8:e8650doi: 10.7717/peerj.8650.
Guo, W., Zhang, Y., Gao, C., Huang, J., Li, J., Wang, R., & Chen, B. (2020). Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody. PeerJ, 8e8650. https://doi.org/10.7717/peerj.8650
Guo, Wenkai, et al. "Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody." PeerJ vol. 8 (2020): e8650. doi: https://doi.org/10.7717/peerj.8650
Guo W, Zhang Y, Gao C, Huang J, Li J, Wang R, Chen B. Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody. PeerJ. 2020 Feb 21;8:e8650. doi: 10.7717/peerj.8650. eCollection 2020. PMID: 32117644; PMCID: PMC7039122.
Copy Download .nbib Format: NLM
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients.

Journal of clinical medicine

Koziolek M, Mueller GA, Dihazi GH, Jung K, Altubar C, Wallbach M, Markovic I, Raddatz D, Jahn O, Karaköse H, Lenz C, Urlaub H, Dihazi A, El Meziane A, Dihazi H.
PMID: 32121033
J Clin Med. 2020 Feb 27;9(3). doi: 10.3390/jcm9030639.

Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study...

Cite
Koziolek M, Mueller GA, Dihazi GH, et al. Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients. J Clin Med. 2020;9(3)doi: 10.3390/jcm9030639.
Koziolek, M., Mueller, G. A., Dihazi, G. H., Jung, K., Altubar, C., Wallbach, M., Markovic, I., Raddatz, D., Jahn, O., Karaköse, H., Lenz, C., Urlaub, H., Dihazi, A., El Meziane, A., & Dihazi, H. (2020). Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients. Journal of clinical medicine, 9(3), . https://doi.org/10.3390/jcm9030639
Koziolek, Michael, et al. "Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients." Journal of clinical medicine vol. 9,3 (2020). doi: https://doi.org/10.3390/jcm9030639
Koziolek M, Mueller GA, Dihazi GH, Jung K, Altubar C, Wallbach M, Markovic I, Raddatz D, Jahn O, Karaköse H, Lenz C, Urlaub H, Dihazi A, El Meziane A, Dihazi H. Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients. J Clin Med. 2020 Feb 27;9(3). doi: 10.3390/jcm9030639. PMID: 32121033; PMCID: PMC7141221.
Copy Download .nbib Format: NLM
Prescribing the dose of dialysis.

Nephrologie & therapeutique

Hanoy M, Le Roy F, Guerrot D.
PMID: 30981387
Nephrol Ther. 2019 Apr;15:S101-S107. doi: 10.1016/j.nephro.2019.03.001.

The concept of dose of dialysis is relatively recent. It evaluates the adequacy of extrarenal clearance, in order to provide the best chances of survival to chronic dialysis patients. Although it presents drawbacks, urea Kt/V is recognized as the...

Cite
Hanoy M, Le Roy F, Guerrot D. Prescription de la dose de dialyse. Prescribing the dose of dialysis. Nephrol Ther. 2019;15:S101-S107doi: 10.1016/j.nephro.2019.03.001.
Hanoy, M., Le Roy, F., & Guerrot, D. (2019). Prescription de la dose de dialyse. Prescribing the dose of dialysis. Nephrologie & therapeutique, 15S101-S107. https://doi.org/10.1016/j.nephro.2019.03.001
Hanoy, Mélanie, et al. "Prescription de la dose de dialyse." Prescribing the dose of dialysis. Nephrologie & therapeutique vol. 15 (2019): S101-S107. doi: https://doi.org/10.1016/j.nephro.2019.03.001
Hanoy M, Le Roy F, Guerrot D. Prescription de la dose de dialyse. Prescribing the dose of dialysis. Nephrol Ther. 2019 Apr;15:S101-S107. doi: 10.1016/j.nephro.2019.03.001. French. PMID: 30981387.
Copy Download .nbib Format: NLM
Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis.

Journal of clinical medicine

Santagati G, Cataldo E, Columbano V, Chatrenet A, Penna D, Pelosi E, Hachemi M, Gendrot L, Nielsen L, Cinquantini F, Saulnier P, Arena V, Boursot C, Piccoli GB.
PMID: 31546847
J Clin Med. 2019 Sep 19;8(9). doi: 10.3390/jcm8091494.

BACKGROUND: The improvements in dialysis have not eliminated long-term problems, including dialysis-related amyloidosis (DRA), caused by Beta-2 microglobulin deposition. Several types of scintigraphy have been tested to detect DRA, none entered the clinical practice. Aim of the study was...

Cite
Santagati G, Cataldo E, Columbano V, et al. Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. J Clin Med. 2019;8(9)doi: 10.3390/jcm8091494.
Santagati, G., Cataldo, E., Columbano, V., Chatrenet, A., Penna, D., Pelosi, E., Hachemi, M., Gendrot, L., Nielsen, L., Cinquantini, F., Saulnier, P., Arena, V., Boursot, C., & Piccoli, G. B. (2019). Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. Journal of clinical medicine, 8(9), . https://doi.org/10.3390/jcm8091494
Santagati, Giulia, et al. "Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis." Journal of clinical medicine vol. 8,9 (2019). doi: https://doi.org/10.3390/jcm8091494
Santagati G, Cataldo E, Columbano V, Chatrenet A, Penna D, Pelosi E, Hachemi M, Gendrot L, Nielsen L, Cinquantini F, Saulnier P, Arena V, Boursot C, Piccoli GB. Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. J Clin Med. 2019 Sep 19;8(9). doi: 10.3390/jcm8091494. PMID: 31546847; PMCID: PMC6781261.
Copy Download .nbib Format: NLM
Urinary Cadmium Threshold to Prevent Kidney Disease Development.

Toxics

Satarug S, Ruangyuttikarn W, Nishijo M, Ruiz P.
PMID: 29723981
Toxics. 2018 May 01;6(2). doi: 10.3390/toxics6020026.

The frequently observed association between kidney toxicity and long-term cadmium (Cd) exposure has long been dismissed and deemed not to be of clinical relevance. However, Cd exposure has now been associated with increased risk of developing chronic kidney disease...

Cite
Satarug S, Ruangyuttikarn W, Nishijo M, et al. Urinary Cadmium Threshold to Prevent Kidney Disease Development. Toxics. 2018;6(2)doi: 10.3390/toxics6020026.
Satarug, S., Ruangyuttikarn, W., Nishijo, M., & Ruiz, P. (2018). Urinary Cadmium Threshold to Prevent Kidney Disease Development. Toxics, 6(2), . https://doi.org/10.3390/toxics6020026
Satarug, Soisungwan, et al. "Urinary Cadmium Threshold to Prevent Kidney Disease Development." Toxics vol. 6,2 (2018). doi: https://doi.org/10.3390/toxics6020026
Satarug S, Ruangyuttikarn W, Nishijo M, Ruiz P. Urinary Cadmium Threshold to Prevent Kidney Disease Development. Toxics. 2018 May 01;6(2). doi: 10.3390/toxics6020026. PMID: 29723981; PMCID: PMC6027056.
Copy Download .nbib Format: NLM
Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Attili S, Ullas B, Lakshm D, Bapsy PP, Lakshm KC, Govind K, Lokana D, Kamal S, Anupam G.
PMID: 27263959
Turk J Haematol. 2007 Dec 05;24(4):181-5.

Malignant pleural effusion in myeloma (MMPE) is a rare terminal event; with a median survival is four months. All the patients usually have multiple poor prognostic factors and none of them (like beta 2-microglobulin, karyotype, Stage of disease, C-reactive...

Cite
Attili S, Ullas B, Lakshm D, et al. Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?. Turk J Haematol. 2007;24(4):181-5
Attili, S., Ullas, B., Lakshm, D., Bapsy, P. P., Lakshm, K. C., Govind, K., Lokana, D., Kamal, S., & Anupam, G. (2007). Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?. Turkish journal of haematology : official journal of Turkish Society of Haematology, 24(4), 181-5.
Attili, Suresh, et al. "Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?." Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 24,4 (2007): 181-5.
Attili S, Ullas B, Lakshm D, Bapsy PP, Lakshm KC, Govind K, Lokana D, Kamal S, Anupam G. Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?. Turk J Haematol. 2007 Dec 05;24(4):181-5. PMID: 27263959.
Copy Download .nbib Format: NLM
Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.

Pharmacology research & perspectives

van Meer L, van Dongen M, Moerland M, de Kam M, Cohen A, Burggraaf J.
PMID: 28596840
Pharmacol Res Perspect. 2017 Jan 17;5(1):e00292. doi: 10.1002/prp2.292. eCollection 2017 Feb.

The antisense compound ISIS 388626 selectively inhibits renal glucose reabsorption by inhibiting the sodium-glucose cotransporter-2 (SGLT2) mRNA expression. It is developed as an insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, and pharmacodynamics after...

Cite
van Meer L, van Dongen M, Moerland M, et al. Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacol Res Perspect. 2017;5(1):e00292doi: 10.1002/prp2.292.
van Meer, L., van Dongen, M., Moerland, M., de Kam, M., Cohen, A., & Burggraaf, J. (2017). Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacology research & perspectives, 5(1), e00292. https://doi.org/10.1002/prp2.292
van Meer, Leonie, et al. "Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects." Pharmacology research & perspectives vol. 5,1 (2017): e00292. doi: https://doi.org/10.1002/prp2.292
van Meer L, van Dongen M, Moerland M, de Kam M, Cohen A, Burggraaf J. Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacol Res Perspect. 2017 Jan 17;5(1):e00292. doi: 10.1002/prp2.292. eCollection 2017 Feb. PMID: 28596840; PMCID: PMC5461644.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 174 entries